- Home
- EW
as 02-21-2025 3:36pm EST
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 42.5B | IPO Year: | 2000 |
| Target Price: | $79.95 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.97 | EPS Growth: | 202.97 |
| 52 Week Low/High: | $58.93 - $96.12 | Next Earning Date: | 02-11-2025 |
| Revenue: | $5,439,500,000 | Revenue Growth: | -9.41% |
| Revenue Growth (this year): | 10.27% | Revenue Growth (next year): | 9.72% |
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LORANGER STEVEN R | EW | Director | Feb 14 '25 | Sell | $76.42 | 5,739 | $438,575.53 | 60,372 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Dec 9 '24 | Sell | $71.68 | 11,250 | $806,405.63 | 30,561 | |
| Chopra Daveen | EW | CVP, TMTT | Dec 6 '24 | Sell | $73.27 | 1,750 | $128,222.68 | 27,583 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
Argus Research
6 days ago
EW: Raising target price to $67.00
Simply Wall St.
8 days ago
The three-year loss for Edwards Lifesciences (NYSE:EW) shareholders likely driven by its shrinking earnings
MT Newswires
11 days ago
Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $71 From $68, Maintains Hold Rating
MT Newswires
11 days ago
Daiwa Adjusts Price Target on Edwards Lifesciences to $77 From $72, Maintains Neutral Rating
Morningstar Research
12 days ago
Analyst Report: Edwards Lifesciences Corporation
Investor's Business Daily
12 days ago
Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion
Benzinga
12 days ago
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
Compare EW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.